Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TNF Pharmaceuticals, Inc. - Common Stock (NQ: TNFA )

0.3622 -0.0168 (-4.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 122,523
Open 0.3803
Bid (Size) 0.3575 (1)
Ask (Size) 0.3600 (40)
Prev. Close 0.3790
Today's Range 0.3551 - 0.3803
52wk Range 0.3500 - 2.160
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
Stay updated with the stocks that are on the move in today's after-hours session.
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill

Performance

YTD
-68.50%
-68.50%
1 Month
-30.01%
-30.01%
3 Month
-70.31%
-70.31%
6 Month
-75.98%
-75.98%
1 Year
-81.89%
-81.89%

More News

Read More
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
From TNF Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
From TNF Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
From TNF Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
From TNF Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNFA Stock Earnings: TNF Pharmaceuticals Reported Results for Q2 2024
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.